A draft of the Lower Health Care Costs Act circulated by the U.S. Senate’s powerful Health, Education, Labor, and Pensions Committee includes a provision that would drastically change how the U.S. develops standards for the strength, quality, and purity of medicines, particularly cutting-edge biologics and biosimilars.

Read this op-ed at The Hill to learn why disrupting the well-functioning current system threatens to undermine the quality of medicines available to American patients.